Skip to Content
Print Share

Generic Pravachol Availability

Pravachol is a brand name of pravastatin, approved by the FDA in the following formulation(s):

PRAVACHOL (pravastatin sodium - tablet;oral)

Has a generic version of Pravachol been approved?

Yes. The following products are equivalent to Pravachol:

pravastatin sodium tablet;oral

  • Manufacturer: ACCORD HLTHCARE
    Approval date: November 17, 2016
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: APOTEX INC
    Approval date: October 23, 2006
    Strength(s): 20MG [AB], 40MG [AB]
  • Manufacturer: APOTEX INC
    Approval date: December 28, 2007
    Strength(s): 80MG [AB]
  • Manufacturer: APPCO PHARMA LLC
    Approval date: April 13, 2018
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: February 2, 2017
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: CIPLA
    Approval date: October 23, 2006
    Strength(s): 20MG [AB], 40MG [AB]
  • Manufacturer: CIPLA
    Approval date: March 22, 2016
    Strength(s): 80MG [AB]
  • Manufacturer: DR REDDYS LABS INC
    Approval date: October 23, 2006
    Strength(s): 20MG [AB], 40MG [AB]
  • Manufacturer: DR REDDYS LABS INC
    Approval date: December 28, 2007
    Strength(s): 80MG [AB]
  • Manufacturer: GLENMARK GENERICS
    Approval date: May 11, 2007
    Strength(s): 20MG [AB], 40MG [AB]
  • Manufacturer: GLENMARK GENERICS
    Approval date: December 28, 2007
    Strength(s): 80MG [AB]
  • Manufacturer: HISUN PHARM HANGZHOU
    Approval date: November 23, 2018
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: LUPIN PHARMS
    Approval date: January 8, 2008
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: May 27, 2010
    Strength(s): 80MG [AB], 20MG [AB], 40MG [AB]
  • Manufacturer: SANDOZ
    Approval date: October 23, 2006
    Strength(s): 20MG [AB], 40MG [AB]
  • Manufacturer: SANDOZ
    Approval date: February 11, 2008
    Strength(s): 80MG [AB]
  • Manufacturer: TEVA
    Approval date: April 24, 2006
    Strength(s): 20MG [AB], 40MG [AB]
  • Manufacturer: TEVA PHARMS
    Approval date: January 15, 2008
    Strength(s): 80MG [AB]
  • Manufacturer: WATSON LABS
    Approval date: October 23, 2006
    Strength(s): 20MG [AB], 40MG [AB]
  • Manufacturer: WATSON LABS
    Approval date: December 28, 2007
    Strength(s): 80MG [AB]
  • Manufacturer: ZYDUS PHARMS USA
    Approval date: April 30, 2008
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pravachol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Add to My Med List
Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide